ArticleMolecular cancer therapeutics2020

RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

Hong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.